HOUSTONAfter controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis. Its authors suggest that efforts to eliminate socioeconomic and healthcare inequalities would significantly reduce the disease's mortality gap between blacks and whites. "Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES, in addition to factors on stage, grade, and co-morbidity," said Xianglin L. Du, MD, PhD, who conducted the study with colleagues from the School of Public Health, University of Texas Health Sciences Center at Houston. The report (on-line at DOI: 10.1002/cncr.22668) will appear in the June issue of Cancer.
The authors aggregated and analyzed data from 10 studies of colorectal cancer patients in which the investigators had adjusted for SES and treatment, and then focused on the association between race/ethnicity and surviving colorectal cancer.The pooled hazard ratio (HR) for blacks vs whites was 1.14 for all-cause mortality and 1.13 for colon-cancer-specific mortality. The test of homogeneity of HR was significant across the nine studies of all-cause mortality but not across the five studies of colon-cancer-specific mortality. The study showed that racial differences in colon cancer survival largely result from racial differences in SES, Dr. Du said, and that "the marginal remaining disadvantages for African-Americans are likely to be explained by factors related to low SES."
Social Factors Likely Explain Colon Ca Racial Disparities
After controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis.
HOUSTONAfter controlling for socioeconomic status (SES) and treatment, African-Americans have only a marginally increased risk of death from colorectal cancer, according to a meta-analysis. Its authors suggest that efforts to eliminate socioeconomic and healthcare inequalities would significantly reduce the disease's mortality gap between blacks and whites. "Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES, in addition to factors on stage, grade, and co-morbidity," said Xianglin L. Du, MD, PhD, who conducted the study with colleagues from the School of Public Health, University of Texas Health Sciences Center at Houston. The report (on-line at DOI: 10.1002/cncr.22668) will appear in the June issue of Cancer.
The authors aggregated and analyzed data from 10 studies of colorectal cancer patients in which the investigators had adjusted for SES and treatment, and then focused on the association between race/ethnicity and surviving colorectal cancer.The pooled hazard ratio (HR) for blacks vs whites was 1.14 for all-cause mortality and 1.13 for colon-cancer-specific mortality. The test of homogeneity of HR was significant across the nine studies of all-cause mortality but not across the five studies of colon-cancer-specific mortality. The study showed that racial differences in colon cancer survival largely result from racial differences in SES, Dr. Du said, and that "the marginal remaining disadvantages for African-Americans are likely to be explained by factors related to low SES."
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Fruquintinib Combo Exhibits Manageable Safety Profile in Pretreated mCRC
Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Neoantigen-Specific TIL/Pembrolizumab Elicits Responses in GI Cancers
A phase 2 study found that treatment with tumor-infiltrating lymphocytes elicited a partial response rate of 15.1% in patients with gastrointestinal cancers.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis
Muhammad Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.
PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases
Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.
Fruquintinib Combo Exhibits Manageable Safety Profile in Pretreated mCRC
Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Neoantigen-Specific TIL/Pembrolizumab Elicits Responses in GI Cancers
A phase 2 study found that treatment with tumor-infiltrating lymphocytes elicited a partial response rate of 15.1% in patients with gastrointestinal cancers.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis
Muhammad Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.
PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases
Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.